Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler bought 23,400 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was purchased at an average price of $21.35 per share, for a total transaction of $499,590.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) traded down 0.67% on Wednesday, hitting $22.25. The stock had a trading volume of 159,325 shares. Accelerate Diagnostics, Inc. has a 12 month low of $19.20 and a 12 month high of $30.45. The stock’s market cap is $1.23 billion. The firm’s 50 day moving average price is $26.51 and its 200-day moving average price is $25.80.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its earnings results on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.40 million. Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. On average, analysts forecast that Accelerate Diagnostics, Inc. will post ($1.20) EPS for the current year.

WARNING: “Jack W. Schuler Buys 23,400 Shares of Accelerate Diagnostics, Inc. (AXDX) Stock” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/jack-w-schuler-buys-23400-shares-of-accelerate-diagnostics-inc-axdx-stock.html.

Several institutional investors have recently modified their holdings of the company. Legal & General Group Plc boosted its stake in shares of Accelerate Diagnostics by 0.3% in the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock worth $123,000 after buying an additional 15 shares during the period. First Manhattan Co. bought a new stake in shares of Accelerate Diagnostics during the first quarter worth $129,000. CLS Investments LLC bought a new stake in shares of Accelerate Diagnostics during the second quarter worth $137,000. SG Americas Securities LLC boosted its stake in shares of Accelerate Diagnostics by 16.8% in the first quarter. SG Americas Securities LLC now owns 5,885 shares of the medical research company’s stock worth $142,000 after buying an additional 846 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Accelerate Diagnostics during the second quarter worth $228,000. Hedge funds and other institutional investors own 38.65% of the company’s stock.

A number of equities research analysts recently commented on the company. Zacks Investment Research downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. BTIG Research reissued a “buy” rating and set a $34.00 price objective on shares of Accelerate Diagnostics in a research note on Wednesday, May 17th. ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub raised Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $32.00 price objective (up from $30.00) on shares of Accelerate Diagnostics in a research note on Monday, June 5th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $33.00.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.